CASTLE BIOSCIENCES, INC. Financials Castle Biosciences, Inc.
Equities
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.33 USD | +6.52% |
|
+19.62% | +12.74% |
| May. 02 | Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
| May. 02 | Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 586.8 | 1,622 | 1,103 | 620.3 | 580.7 | 671.7 | - | - |
| Enterprise Value (EV) 1 | 513.1 | 1,212 | 773.4 | 361.7 | 337.6 | 422.9 | 471.1 | 467.7 |
| P/E ratio | 99.5 x | -124 x | -34.6 x | -9.12 x | -10.1 x | -15.3 x | -13.1 x | -21.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 11.3 x | 25.9 x | 11.7 x | 4.53 x | 2.64 x | 2.58 x | 2.57 x | 2.26 x |
| EV / Revenue | 9.89 x | 19.3 x | 8.22 x | 2.64 x | 1.54 x | 1.62 x | 1.8 x | 1.57 x |
| EV / EBITDA | 66.8 x | -200 x | -21.1 x | -5.8 x | -6.07 x | -10.5 x | -9.54 x | -16.2 x |
| EV / FCF | 84.4 x | 237 x | -34.4 x | -7.65 x | -17.5 x | -75.5 x | 210 x | 20.2 x |
| FCF Yield | 1.18% | 0.42% | -2.9% | -13.1% | -5.7% | -1.33% | 0.48% | 4.96% |
| Price to Book | 3.5 x | 3.06 x | 2.62 x | 1.54 x | 1.48 x | 1.68 x | 1.76 x | 1.73 x |
| Nbr of stocks (in thousands) | 17,074 | 24,156 | 25,730 | 26,352 | 26,911 | 27,607 | - | - |
| Reference price 2 | 34.37 | 67.15 | 42.87 | 23.54 | 21.58 | 24.33 | 24.33 | 24.33 |
| Announcement Date | 3/10/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 51.86 | 62.65 | 94.08 | 137 | 219.8 | 260.6 | 261.1 | 297.4 |
| EBITDA 1 | 7.686 | -6.07 | -36.67 | -62.31 | -55.65 | -40.1 | -49.37 | -28.81 |
| EBIT 1 | 7.328 | -6.542 | -40.08 | -72.86 | -67.98 | -51.6 | -61.81 | -38.27 |
| Operating Margin | 14.13% | -10.44% | -42.6% | -53.16% | -30.93% | -19.8% | -23.67% | -12.87% |
| Earnings before Tax (EBT) 1 | 5.349 | -10.2 | -40.01 | -68.9 | -57.36 | -44.27 | -54.15 | -33.96 |
| Net income 1 | 2.991 | -10.28 | -31.29 | -67.14 | -57.47 | -44.19 | -52.76 | -31.88 |
| Net margin | 5.77% | -16.42% | -33.26% | -48.99% | -26.15% | -16.95% | -20.21% | -10.72% |
| EPS 2 | 0.3455 | -0.5400 | -1.240 | -2.580 | -2.140 | -1.591 | -1.851 | -1.130 |
| Free Cash Flow 1 | 6.078 | 5.114 | -22.47 | -47.29 | -19.25 | -5.605 | 2.243 | 23.18 |
| FCF margin | 11.72% | 8.16% | -23.88% | -34.51% | -8.76% | -2.15% | 0.86% | 7.79% |
| FCF Conversion (EBITDA) | 79.08% | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 203.21% | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25.04 | 26.85 | 34.84 | 37.01 | 38.34 | 42.04 | 50.14 | 61.49 | 66.12 | 72.97 | 68.74 | 58.16 | 60.78 | 59.47 | 64.37 |
| EBITDA 1 | -13.72 | -11.35 | -10.88 | -8.275 | -19.99 | -15.1 | -5.268 | 6.577 | -2.434 | -2.131 | -8.733 | -14.97 | -13.6 | - | - |
| EBIT 1 | -15.17 | -21.95 | -22.66 | -21.69 | -22.83 | -31.52 | -21.16 | -9.64 | -5.658 | -5.471 | -9.503 | -18.98 | -17.68 | -21.94 | -18.18 |
| Operating Margin | -60.59% | -81.76% | -65.04% | -58.6% | -59.55% | -74.99% | -42.2% | -15.68% | -8.56% | -7.5% | -13.83% | -32.64% | -29.08% | -36.9% | -28.24% |
| Earnings before Tax (EBT) 1 | -15.16 | -24.49 | -3.605 | -20.25 | -20.56 | -29.19 | -18.76 | -6.873 | -2.541 | -2.489 | -7.975 | -17.5 | -16.33 | -20.73 | -16.96 |
| Net income 1 | -6.43 | -24.62 | -1.648 | -20.25 | -20.62 | -29.2 | -18.78 | -6.905 | -2.58 | -2.534 | -8.144 | -17.4 | -16.11 | -19.03 | -15.6 |
| Net margin | -25.68% | -91.7% | -4.73% | -54.71% | -53.78% | -69.47% | -37.45% | -11.23% | -3.9% | -3.47% | -11.85% | -29.91% | -26.51% | -32% | -24.23% |
| EPS 2 | -0.2500 | -0.9700 | -0.0600 | -0.7700 | -0.7800 | -1.100 | -0.7000 | -0.2600 | -0.1000 | -0.0900 | -0.2950 | -0.6250 | -0.5750 | -0.6520 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/8/22 | 11/2/22 | 2/28/23 | 5/3/23 | 8/2/23 | 11/2/23 | 2/28/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 73.7 | 410 | 330 | 259 | 243 | 249 | 201 | 204 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 6.08 | 5.11 | -22.5 | -47.3 | -19.2 | -5.61 | 2.24 | 23.2 |
| ROE (net income / shareholders' equity) | 21% | -4.11% | -7.56% | -16.6% | -14.5% | -11.2% | -16.1% | -10.5% |
| ROA (Net income/ Total Assets) | 4.21% | -3.68% | -6.94% | -14.8% | -12.8% | -9.45% | -13.3% | -8.35% |
| Assets 1 | 71.08 | 279.5 | 451 | 455 | 450.3 | 467.6 | 398.2 | 381.8 |
| Book Value Per Share 2 | 9.830 | 22.00 | 16.40 | 15.30 | 14.60 | 14.50 | 13.80 | 14.00 |
| Cash Flow per Share 2 | 0.8100 | 0.5200 | -0.7200 | -2.170 | -0.2100 | -0.1000 | -0.4500 | 0.3900 |
| Capex 1 | 0.94 | 4.75 | 3.48 | 5.63 | 13.6 | 17.8 | 11.5 | 11.5 |
| Capex / Sales | 1.81% | 7.58% | 3.7% | 4.11% | 6.2% | 6.82% | 4.41% | 3.85% |
| Announcement Date | 3/10/20 | 3/8/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.33
USD
Average target price
34
USD
Spread / Average Target
+39.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.74% | 672M | |
| -1.89% | 12.56B | |
| -9.59% | 7.68B | |
| -1.31% | 5.29B | |
| +21.82% | 5.24B | |
| +0.02% | 4.57B | |
| -50.89% | 3.29B | |
| +6.42% | 2.6B | |
| -10.02% | 2.2B | |
| -8.29% | 1.79B |
- Stock Market
- Equities
- CSTL Stock
- Financials Castle Biosciences, Inc.
